Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


16.07.2018

1 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Lett
1 Clin Cancer Res
11 Gynecol Oncol
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. KIECHLE M, Dukatz R, Yahiaoui-Doktor M, Berling A, et al
    Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1).
    BMC Cancer. 2017;17:752.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  2. BHOWMIK S, Bhowmick S, Maiti K, Chakra A, et al
    Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil((R)) or Caelyx((R)) in advanced ovarian cancer.
    Cancer Chemother Pharmacol. 2018 Jul 11. pii: 10.1007/s00280-018-3643.
    PubMed     Text format     Abstract available


    Cancer Lett

  3. KARTHIKEYAN S, Russo A, Dean M, Lantvit DD, et al
    Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
    Cancer Lett. 2018;433:221-231.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  4. MCNEISH IA
    Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack?
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1731.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. MOORE KN, Mirza MR, Matulonis UA
    The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Gynecol Oncol. 2018;149:214-220.
    PubMed     Text format     Abstract available

  6. OZA A, Kaye S, Van Tornout J, Sessa C, et al
    Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Gynecol Oncol. 2018 Feb 14. pii: S0090-8258(18)30058.
    PubMed     Text format     Abstract available

  7. KELLENBERGER LD, Petrik J
    Hyperglycemia promotes insulin-independent ovarian tumor growth.
    Gynecol Oncol. 2018 Feb 17. pii: S0090-8258(18)30122.
    PubMed     Text format     Abstract available

  8. JAREID M, Thalabard JC, Aarflot M, Bovelstad HM, et al
    Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30125.
    PubMed     Text format     Abstract available

  9. HUVILA J, Laajala TD, Edqvist PH, Mardinoglu A, et al
    Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30135.
    PubMed     Text format     Abstract available

  10. BUSKWOFIE A, Huang Y, Tergas AI, Hou JY, et al
    Impact of hospital volume on racial disparities and outcomes for endometrial cancer.
    Gynecol Oncol. 2018 Mar 2. pii: S0090-8258(18)30138.
    PubMed     Text format     Abstract available

  11. LIAO CI, Chow S, Chen LM, Kapp DS, et al
    Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30069.
    PubMed     Text format     Abstract available

  12. KIM J, Kim S, Lee HS, Yang W, et al
    Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30132.
    PubMed     Text format     Abstract available

  13. MATSUO K, Yabuno A, Hom MS, Shida M, et al
    Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30131.
    PubMed     Text format     Abstract available

  14. DENG K, Yang C, Tan Q, Song W, et al
    Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31004.
    PubMed     Text format     Abstract available

  15. TIMMERMANS M, van der Aa MA, Lalisang RI, Witteveen PO, et al
    Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31017.
    PubMed     Text format     Abstract available


    PLoS One

  16. TEA MM, Tan YY, Staudigl C, Eibl B, et al
    Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
    PLoS One. 2018;13:e0200559.
    PubMed     Text format     Abstract available

  17. EARP M, Tyrer JP, Winham SJ, Lin HY, et al
    Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.
    PLoS One. 2018;13:e0197561.
    PubMed     Text format     Abstract available

  18. YEH CC, Su FH, Tzeng CR, Muo CH, et al
    Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study.
    PLoS One. 2018;13:e0194011.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: